Literature DB >> 11571508

Obesity and autologous stem cell transplantation in acute myeloid leukemia.

G Meloni1, A Proia, S Capria, A Romano, G Trapé, S M Trisolini, M Vignetti, F Mandelli.   

Abstract

In the bone marrow transplant setting, several authors hypothesized that severely overweight patients are at increased risk of transplant-related toxicity, but different definitions of obesity, different body weight groupings and heterogeneous samples of patients were analyzed. To overcome these limitations, we retrospectively considered a homogeneous group of 54 patients (median age 36.5 years), with a diagnosis of de novo acute myeloid leukemia (AML), autografted in first complete remission (CR) with the Bu-Cy2 conditioning regimen, dosed on actual body weight. Patients were classified into three groups (obese, non-obese, underweight) using body mass index (BMI = kg/m(2)); for each group we analyzed transplant-related toxicity and mortality, overall survival and disease-free survival (OS/DFS). In spite of the relatively small number of patients, in our results high BMI appears a predictive factor for an increase of treatment-related toxicity and mortality. Moreover, 30 (55%) patients are currently alive in continuous CR, and after a median follow-up of 76.5 months (range 14-137) statistically significant differences in OS and DFS were detected between obese and non-obese groups (P = 0.012 and 0.021, respectively). Our study suggests that obesity may represent an independent risk factor for autograft in AML and further investigations are warranted.

Entities:  

Mesh:

Year:  2001        PMID: 11571508     DOI: 10.1038/sj.bmt.1703145

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning.

Authors:  Gülsan Türköz Sucak; Elif Suyanı; Nuran Ahu Baysal; Şermin Altındal; Merih Kizil Çakar; Şahika Zeynep Akı; Zeynep Arzu Yeğin; Nevin Şanlıer
Journal:  Int J Hematol       Date:  2011-12-09       Impact factor: 2.490

Review 2.  Autologous stem cell transplantation in hematological malignancies.

Authors:  Norbert-Claude Gorin
Journal:  Springer Semin Immunopathol       Date:  2004-10-07

3.  Impact of being overweight on outcomes of hematopoietic SCT: a meta-analysis.

Authors:  M Nakao; D Chihara; A Niimi; R Ueda; H Tanaka; Y Morishima; K Matsuo
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

4.  Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.

Authors:  Dan T Vogl; Tao Wang; Waleska S Pérez; Edward A Stadtmauer; Daniel F Heitjan; Hillard M Lazarus; Robert A Kyle; Ram Kamble; Daniel Weisdorf; Vivek Roy; John Gibson; Karen Ballen; Leona Holmberg; Asad Bashey; Philip L McCarthy; Cesar Freytes; Dipnarine Maharaj; Angelo Maiolino; David Vesole; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

5.  Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.

Authors:  Nobuko Hijiya; John C Panetta; Yinmei Zhou; Emily P Kyzer; Scott C Howard; Sima Jeha; Bassem I Razzouk; Raul C Ribeiro; Jeffrey E Rubnitz; Melissa M Hudson; John T Sandlund; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

6.  Evolution of nutritional status in patients with autologous and allogeneic hematopoietic stem cell transplant.

Authors:  Romina L Barritta de Defranchi; Andrea Bordalejo; Inés Cañueto; Angeles Villar; Elizabet Navarro
Journal:  Support Care Cancer       Date:  2014-10-28       Impact factor: 3.603

7.  Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia.

Authors:  Collin C Barker; Manza-A Agovi; Brent Logan; Hillard M Lazarus; Karen K Ballen; Vikas Gupta; Gregory A Hale; Haydar Frangoul; Vincent Ho; J Douglas Rizzo; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-14       Impact factor: 5.742

Review 8.  Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.

Authors:  Claudia Langebrake; Friederike Bernhardt; Michael Baehr; Nicolaus Kröger; Axel R Zander
Journal:  Int J Clin Pharm       Date:  2011-09-29

9.  Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Noga Shem-Tov; Myriam Labopin; Leila Moukhtari; Fabio Ciceri; Jordi Esteve; Sebastian Giebel; Norbert-Claude Gorin; Christopher Schmid; Avichai Shimoni; Arnon Nagler; Mohamad Mohty
Journal:  Oncologist       Date:  2014-12-05

10.  Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.

Authors:  Conrad V Fernandez; James Anderson; Norman E Breslow; Jeffrey S Dome; P E Grundy; Elizabeth J Perlman; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.